On 16 November 2017, Orphazyme A/S ("Orphazyme") held an extraordinary general meeting at which Anders Hedegaard and Catherine Moukheibir were elected as new members of the Board of Directors as set out in the offering circular (the "Offering Circular") published on 6 November 2017 in connection with the Initial Public Offering and admission to trading and official listing of Orphazyme on Nasdaq Copenhagen A/S.
Anders Hedegaard is currently chief executive officer of GN Store Nord A/S and GN Hearing A/S and was previously CEO of Bavarian Nordic A/S. Anders Hedegaard holds a Master of Science in Chemical Engineering and Biochemistry from the Technical University of Denmark.
Catherine Moukheibir is currently chairman of the board of directors of MedDay Pharmaceuticals SA, member of the board of directors of Zealand Pharma A/S (publ) and Genkyotex SA (publ), as well as a member of the board of directors of Ablynx NV (publ) and Cerenis Therapeutics SA (publ). Catherine Moukheibir holds a Master in Economics and an MBA degree, both from Yale University.
As described in the Offering Circular, Martin Rahbek Kornum, Nanna Lüneborg and Patrick Krol resigned from the Board of Directors in connection with the extraordinary general meeting.
The Board of Directors is now composed as follows: